

PERKINS DISCOVERY FUND

Schedule of Investments

June 30, 2023 (unaudited)

	<u>Shares</u>	<u>Fair Value</u>
98.74% COMMON STOCKS		
1.78% BIOTECHNOLOGY		
Journey Medical Corp. ^(A)	22,000	\$ 34,980
MDxHealth SA ^(A)	35,000	<u>119,350</u>
		<u>154,330</u>
8.69% CONSUMER DISCRETIONARY		
iMedia Brands, Inc. ^(A)	35,700	4,713
Magnite, Inc. ^(A)	20,000	273,000
Perion Network Ltd. ^(A)	15,500	<u>475,385</u>
		<u>753,098</u>
1.38% FINANCIALS		
FlexShopper, Inc. ^(A)	93,500	<u>119,680</u>
21.52% HEALTH CARE DRUGS/SERVICES		
ANI Pharmaceuticals, Inc. ^(A)	7,100	382,193
NeoGenomics, Inc. ^(A)	22,000	353,540
Veracyte, Inc. ^(A)	21,500	547,605
Vericel Corp. ^(A)	15,500	<u>582,335</u>
		<u>1,865,673</u>
5.69% HEALTH CARE MANUFACTURING		
AtriCure, Inc. ^(A)	10,000	<u>493,600</u>
11.46% HEALTH CARE SUPPLIES		
Axogen, Inc. ^(A)	32,500	296,725
BioLife Solutions, Inc. ^(A)	15,500	342,550
Cryoport, Inc. ^(A)	10,000	172,500
Exagen, Inc. ^(A)	16,500	47,850
Perspective Therapeutics, Inc. ^(A)	200,000	<u>133,600</u>
		<u>993,225</u>

PERKINS DISCOVERY FUND

Schedule of Investments - continued

June 30, 2023 (unaudited)

	Shares	Fair Value
12.75% HEALTH CARE SUPPORT		
Natera, Inc. ^(A)	11,000	\$ 535,260
Option Care Health, Inc. ^(A)	14,500	471,105
Rockwell Medical, Inc. ^(A)	18,181	99,268
		1,105,633
 6.55% HEALTH CARE TECHNOLOGY		
Fortress Biotech, Inc. ^(A)	69,500	38,225
OptimizeRx Corp. ^(A)	14,000	200,060
Streamline Health Solutions, Inc. ^(A)	131,500	167,005
Tactile Systems Technology, Inc. ^(A)	6,500	162,045
		567,335
 17.47% INFORMATION TECHNOLOGY		
Airgain, Inc. ^(A)	15,500	83,700
Akoustis Technologies, Inc. ^(A)	29,000	92,220
Cantaloupe, Inc. ^(A)	43,000	342,280
Digi International, Inc. ^(A)	11,800	464,802
Inuvo, Inc. ^(A)	514,500	114,219
Perficient, Inc. ^(A)	5,000	416,650
		1,513,871
 11.45% SOFTWARE SERVICES		
Asure Software, Inc. ^(A)	33,000	401,280
ePlus, Inc. ^(A)	10,500	591,150
		992,430
 98.74% TOTAL COMMON STOCKS		
		\$ 8,558,875

PERKINS DISCOVERY FUND

Schedule of Investments - continued

June 30, 2023 (unaudited)

	Shares	Fair Value
1.30% SHORT-TERM INVESTMENTS		
Fidelity Investments Money Market Government Portfolio Institutional Class 4.99% ^(B)	113,108	\$ 113,108
100.04% TOTAL INVESTMENTS		8,671,983
(0.04%) Liabilities in excess of other assets		(3,709)
100.00% NET ASSETS		\$ 8,668,274

^(A) Non-income producing

^(B) Effective 7 day yield as of June 30, 2023

PERKINS DISCOVERY FUND

Schedule of Investments - continued

June 30, 2023 (unaudited)

In accordance with U.S. GAAP, “fair value” is defined as the price that a Fund would receive upon selling an investment in an orderly transaction to an independent buyer in the principal or most advantageous market for the investment. Various inputs are used in determining the value of a Fund’s investments. U.S. GAAP established a three-tier hierarchy of inputs to establish a classification of fair value measurements for disclosure purposes. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). Level 3 includes significant unobservable inputs (including the Fund’s own assumptions in determining fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund’s investments as of June 30, 2023:

	Level 1	Level 2	Level 3	Total
	Quoted Prices	Other Significant Observable Inputs	Significant Unobservable Inputs	
Common Stocks	\$ 8,558,875	\$ —	\$ —	\$ 8,558,875
Short-Term Investments	113,108	—	—	113,108
Total Investments	\$ 8,671,983	\$ —	\$ —	\$ 8,671,983

The Fund held no Level 3 securities at any time during the period.

There were no transfers into or out of Levels 1 and 2 during the period ended June 30, 2023.

At June 30, 2023, the cost of investments for Federal income tax purposes has been estimated since the final tax characteristics cannot be determined until fiscal year end. Cost of securities for Federal income tax purpose is \$5,487,539 and the related tax-based net unrealized appreciation (depreciation) consists of:

Gross unrealized appreciation . . .	\$ 4,967,813
Gross unrealized depreciation . . .	(1,783,369)
Net unrealized appreciation	\$ 3,184,444